GNH USA

Europe — EMA

Lacosamida Aurovitas

GNH USA supplies Lacosamida Aurovitas (Lacosamide), a sodium channel blocker for partial‑onset seizures.

Lacosamide

Request sourcing

1
Pack/s

What is Lacosamide?

Lacosamide, the active ingredient in Lacosamida Aurovitas, is a sodium channel blocker presented as an oral dosage form for oral use. It is used as adjunctive therapy to control partial‑onset seizures in patients with epilepsy.

GNH USA supplies Lacosamida Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets.

What is Lacosamide used for?

Lacosamide is an antiepileptic drug indicated for seizure disorders.

Partial‑onset seizures: reduces seizure frequency when added to existing therapy Focal seizures: provides adjunctive control in patients with refractory focal epilepsy Epilepsy (generalized): contributes to overall seizure management as part of combination therapy

What are the side effects of Lacosamide?

Lacosamide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness - Headache - Nausea - Fatigue - Blurred vision - Coordination problems

Serious or Rare Side Effects: - Cardiac arrhythmias (e.g., PR interval prolongation) - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Hypersensitivity reactions (e.g., anaphylaxis) - Mood changes or suicidal ideation

What precautions apply to Lacosamide?

When prescribing Lacosamide, clinicians should consider several precautionary measures. - Cardiac monitoring: assess ECG for PR interval changes - Renal function: adjust dose in severe impairment - Hepatic function: use caution in patients with liver disease - Discontinuation: avoid abrupt cessation to prevent seizure worsening - Store at room temperature: keep in original container, protect from moisture

What does Lacosamide interact with?

Lacosamide can interact with other medicines, requiring attention to potential changes in efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may markedly reduce lacosamide levels - Concurrent use with other sodium‑channel blockers (e.g., lamotrigine, topiramate): may increase risk of CNS depression

Moderate Interactions (Monitor Closely): - Hormonal contraceptives: may decrease contraceptive effectiveness - Alcohol: may enhance dizziness and sedation - Other antiepileptic drugs: may require dose adjustments to maintain seizure control

Frequently asked questions

What is Lacosamida Aurovitas used for?+
Lacosamida Aurovitas contains lacosamide, which is prescribed as an adjunctive treatment for patients with partial‑onset (focal) seizures and other forms of epilepsy when additional seizure control is needed.
How does lacosamide work?+
Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neurons. This stabilizes hyper‑excitable neuronal membranes, reduces repetitive firing, and helps prevent the abnormal electrical activity that leads to seizures.
What is the usual dose of Lacosamida Aurovitas?+
The dosing regimen for lacosamide is individualized. A qualified prescriber determines the appropriate dose and titration schedule based on the patient’s clinical condition, response, and any relevant laboratory values.
Is Lacosamida Aurovitas safe during pregnancy or breastfeeding?+
Safety data for lacosamide in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against possible risks and discuss alternative options when treating pregnant or nursing individuals.
How do I order Lacosamida Aurovitas from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.
How does lacosamide compare with other antiepileptic drugs?+
Lacosamide’s unique mechanism—enhancing slow sodium‑channel inactivation—differs from many older agents that target fast inactivation. Compared with drugs such as carbamazepine, lacosamide often has a lower risk of drug‑induced hyponatremia and may be better tolerated in patients who experience cognitive side effects from other medications.
What are the storage and handling requirements for Lacosamida Aurovitas?+
Lacosamida Aurovitas should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from excess moisture and direct sunlight to maintain its stability.
How is Lacosamida Aurovitas administered?+
The medication is taken orally, usually as tablets or capsules, with or without food. Patients should follow the administration instructions provided by their healthcare professional.
What are the most serious risks associated with lacosamide?+
Serious adverse events include cardiac conduction abnormalities such as PR‑interval prolongation, severe skin reactions like Stevens‑Johnson syndrome, hypersensitivity reactions including anaphylaxis, and mood changes that may lead to suicidal thoughts. Prompt medical attention is required if any of these occur.
Who should not use Lacosamida Aurovitas?+
Patients with known hypersensitivity to lacosamide or any component of the formulation should avoid the product. Caution is also advised for individuals with significant cardiac conduction disorders, severe renal impairment, or uncontrolled hepatic disease, and the medication should be used only under medical supervision in these cases.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Product details

Drug
Lacosamide
Route
Oral Use
Manufacturer
Aurovitas Spain,s.A.U.
Origin
EU

Related products